Should you short it before the Earnings result? : Sonnet BioTherapeutics (NASDAQ:SONN)

Earnings results for Sonnet BioTherapeutics (NASDAQ:SONN)

Sonnet BioTherapeutics Holdings, Inc. is estimated to report earnings on 08/13/2021. The upcoming earnings date is derived from an algorithm based on a company’s historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. The reported EPS for the same quarter last year was $-0.44.

Sonnet BioTherapeutics last posted its quarterly earnings results on May 17th, 2021. The reported ($0.32) EPS for the quarter. Sonnet BioTherapeutics has generated $0.00 earnings per share over the last year (($6.44) diluted earnings per share). Sonnet BioTherapeutics has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Friday, August 13th, 2021 based off prior year’s report dates.

Analyst Opinion on Sonnet BioTherapeutics (NASDAQ:SONN)

1 Wall Street analysts have issued ratings and price targets for Sonnet BioTherapeutics in the last 12 months. Their average twelve-month price target is $8.00, predicting that the stock has a possible upside of 684.31%. The high price target for SONN is $8.00 and the low price target for SONN is $8.00. There are currently 1 buy rating for the stock, resulting in a consensus rating of “Buy.”

Sonnet BioTherapeutics has received a consensus rating of Buy. The company’s average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings. According to analysts’ consensus price target of $8.00, Sonnet BioTherapeutics has a forecasted upside of 684.3% from its current price of $1.02. Sonnet BioTherapeutics has received no research coverage in the past 90 days.

Dividend Strength: Sonnet BioTherapeutics (NASDAQ:SONN)

Sonnet BioTherapeutics does not currently pay a dividend. Sonnet BioTherapeutics does not have a long track record of dividend growth.

Insiders buying/selling: Sonnet BioTherapeutics (NASDAQ:SONN)

In the past three months, Sonnet BioTherapeutics insiders have bought more of their company’s stock than they have sold. Specifically, they have bought $88,200.00 in company stock and sold $0.00 in company stock. Only 6.90% of the stock of Sonnet BioTherapeutics is held by insiders. Only 3.42% of the stock of Sonnet BioTherapeutics is held by institutions.

Earnings and Valuation of Sonnet BioTherapeutics (NASDAQ:SONN

The P/E ratio of Sonnet BioTherapeutics is -0.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Sonnet BioTherapeutics is -0.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Sonnet BioTherapeutics has a P/B Ratio of 4.64. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

More latest stories: here